See SI Appendix for detailed information. Reagents were purchased from Sigma-Aldrich unless otherwise mentioned. All animal protocols were approved by the Institutional Animal Ethics Committee (IAEC) formulated by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), India. For reagents, plasmids, cell culture, and animal procedures, see SI Appendix, Sections 1–3. LDs were prepared from rat liver by sucrose density gradient (SI Appendix, Sections 5 and 8) and assayed for in vitro motility (SI Appendix, Section 6). ALDs prepared using glyceryl trioleate and PC were incubated with liver lysate before centrifugation and Western blotting (SI Appendix, Section 15). Cells infected with adenoviral shRNA were separated into LDs and soluble and membrane fractions (SI Appendix, Section 16). Rats were injected with kinesin-1 shRNA plasmid complexed with jetPEI, and later with Triton WR-1339. Serum was prepared for TG estimation and fractionation of ApoB containing lipoproteins (SI Appendix, Sections 17 and 23). Cellular and secreted TG was measured by LC-MS (SI Appendix, Section 21). ApoB was measured in cells and in liver lysates by Western blotting after immunoprecipitation (SI Appendix, Section 22). Liver lysate was subjected to ultracentrifugation to prepare microsomes and the membrane proteins were isolated for substrate hydrolysis assay (SI Appendix, Sections 24 and 25). Huh7.5 cells were infected with adenoviral shRNA followed by transfection with HCV-JFH-1 RNA. Cells and media were used for RNA isolation and qRT-PCR (SI Appendix, Section 26). See details of statistical analysis in SI Appendix, Section 27.